Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes (LymphoEnergy)

May 11, 2026 updated by: University Hospital, Lille

Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis

Peripheral blood mononuclear cells (PBMC) and platelets could be interesting ex vivo models to study brain diseases. Indeed, there is no access to neurons from patients. However, PBMC can exhibit different physiopathological mechanisms that are ubiquitous (i.e. oxidative stress, mitochondriopathy with energy metabolism, inflammation, protein folding, iron metabolism and programmed cell death ...). The platelets are pivotal in the healing system with large range of growth factors. A new therapeutic concept of conservative iron chelation with deferiprone for neuroprotection is under development.

The action of deferiprone on the different mechanisms and notably the oxidative stress are to obtain from a collection of PBMC and platelets from patient having Parkinson's disease and Amyotrophic lateral sclerosis and healthy controls to study ex vivo.

PBMC and platelets will be stored for future analyses.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study collection of PBMC and platelets from 30 patient having Parkinson's disease 30 patients having Amyotrophic lateral sclerosis and 30 healthy controls.

The collection will be performed either by cytapheresis for half of the patient and by collecting the whole blood for the other half.

PBMC and platelets will be stored at minus 80°C. PBMC of patients and controls are exposed ex vivo to different pathological condition (mainly Hydrogen peroxide, menadione, hypoxia...) with and without deferiprone to analyse whether the level of oxidative stress (Reactive Oxygen Species and notably hydroxyl radical with hydroxypethidine probe with flow cytometry) is reduced under deferiprone (primary criterion. Secondary analyses will concern the level of iron, the energy metabolism (aerobic versus anaerobic and the level of Adenosine triphosphate production), the type of cell death (apoptosis, autophagy and new programmed cell death: Ferroptosis) and inflammation. Finally, the level of growth factors and their effectiveness will be studied from platelets.

Study Type

Interventional

Enrollment (Actual)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Lille, France
        • Hôpital Roger Salengro, CHRU de Lille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Parkinson's disease according to Movement Disorders Society criteria
  • Amyotrophic Lateral Sclerosis according to El escorial criteria
  • Age and sex matched healthy controls

Exclusion Criteria:

  • Severe comorbidities (cancer, other degenerative diseases, hemopathy, inflammatory diseases)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Parkinson's disease
ex vivo analysis of lymphocytes from 30 patients with Parkinson's disease with deferiprone and placebo treatment
Drug: deferiprone
to test the action of deferiprone on lymphocytes from patients and controls ex vivo
Other Names:
  • FERRIPROX
Drug: placebo
to control the action of placebo on lymphocytes from patients and controls ex vivo
Active Comparator: Amyotrophic lateral sclerosis
ex vivo analysis of lymphocytes from 30 patients with Amyotrophic lateral sclerosis with deferiprone and placebo treatment
Drug: deferiprone
to test the action of deferiprone on lymphocytes from patients and controls ex vivo
Other Names:
  • FERRIPROX
Drug: placebo
to control the action of placebo on lymphocytes from patients and controls ex vivo
Placebo Comparator: healthy age and sex matched controls
ex vivo analysis of lymphocytes from 30 healthy age and sex matched controls with deferiprone and placebo treatment
Drug: deferiprone
to test the action of deferiprone on lymphocytes from patients and controls ex vivo
Other Names:
  • FERRIPROX
Drug: placebo
to control the action of placebo on lymphocytes from patients and controls ex vivo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
hydroxyl radical measured
Time Frame: 12 months
hydroxypethidine probe with Fluorescence-activated cell sorting
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
adenosine triphosphate production measured by seahorse
Time Frame: 12 months
seahorse experimentation
12 months
oxygen consumption measured by seahorse
Time Frame: 12 months
seahorse experimentation
12 months
free reactive iron (ferrous iron)
Time Frame: 12 months
calceine assay
12 months
lipid peroxidation measured by Fluorescence-activated cell sorting
Time Frame: 12 months
flow cytometry with bodipy probe
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Lille

Investigators

  • Principal Investigator: David DEVOS, MD, PhD, University Hospital, Lille

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2011

Primary Completion (Actual)

October 1, 2019

Study Completion (Actual)

March 1, 2020

Study Registration Dates

First Submitted

August 3, 2016

First Submitted That Met QC Criteria

August 22, 2016

First Posted (Estimated)

August 26, 2016

Study Record Updates

Last Update Posted (Actual)

May 14, 2026

Last Update Submitted That Met QC Criteria

May 11, 2026

Last Verified

March 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2010_29
  • 2010-A01216-33 (Other Identifier: ID-RCB number, ANSM)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson's Disease

Clinical Trials on deferiprone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe